Pidotimod exacerbates allergic pulmonary infection in an OVA mouse model of asthma

Molecular Medicine Reports

Volumn 16, Issue 4, 2017, Pages 4151-4158

  Fu, Luo Qin ^a,b   Li, Ya Li ^a   Fu, Ai Kun ^a   Wu, Yan Ping ^a   Wang, Yuan Yuan ^a   Hu, Sheng Lan ^c   Li, Wei Fen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c INSTITUTE OF ANIMAL SCIENCE   (China)

Author keywords

Arg1; Asthma; Eosinophils; FIZZ1; Inflammation; Mucus; Pidotimod

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; PIDOTIMOD; ARGINASE; PYROGLUTAMIC ACID; RETNLA PROTEIN, MOUSE; SIGNAL PEPTIDE; THIAZOLIDINE DERIVATIVE;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DOWN REGULATION; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TH2 CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ASTHMA; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; CELL DIFFERENTIATION; COMPLICATION; DISEASE MODEL; DRUG EFFECT; HYPERSENSITIVITY; IMMUNOLOGY; LUNG; METABOLISM; METAPLASIA; MUCUS; PATHOLOGY; RESPIRATORY TRACT INFECTION;

ANIMALS; ARGINASE; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EOSINOPHILS; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; METAPLASIA; MICE, INBRED C57BL; MUCUS; OVALBUMIN; PYRROLIDONECARBOXYLIC ACID; RESPIRATORY TRACT INFECTIONS; TH2 CELLS; THIAZOLIDINES;

EID: 85028695016     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2017.7046     Document Type: Article

References (43)

1. Wenzel SE: Asthma: Defining of the persistent adult phenotypes. Lancet 368:804-813, 2006.
2. Barnes PJ, Chung KF and Page CP: Inflammatory mediators of asthma: An update. Pharmacol Rev 50:515-596, 1999.
3. Holt PG, Macaubas C, Stumbles PA and Sly PD: The role of allergy in the development of asthma. Nature 402(6760 Suppl):B12-B17, 1999.
4. Balhara J and Gounni AS: The alveolar macrophages in asthma: A double-edged sword. Mucosal Immunol 5:605-609, 2012.
5. Ni Z, Tang J, Cai Z, Yang W, Zhang L, Chen Q, Zhang L and Wang X: A new pathway of glucocorticoid action for asthma treatment through the regulation of PTEN expression. Respir Res 12:47, 2011.
6. Baatjes AJ, Sehmi R, Saito H, Cyr MM, Dorman SC, Inman MD, O'Byrne PM and Denburg JA: Anti-allergic therapies: Effects on eosinophil progenitors. Pharmacol Ther 95:63-72, 2002.
7. Jahnsen FL, Haye R, Gran E, Brandtzaeg P and Johansen FE: Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 163:1545-1551, 1999.
8. Akdis CA: Therapies for allergic inflammation: Refining strategies to induce tolerance. Nat Med 18:736-749, 2012.
9. Dahl R: Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100:1307-1317, 2006.
10. Riboldi P, Gerosa M and Meroni PL: Pidotimod: A reappraisal. Int J Immunopathol Pharmacol 22:255-262, 2009.
11. Licari A, De Amici M, Nigrisoli S, Marseglia A, Caimmi S, Artusio L and Marseglia GL: Pidotimod may prevent recurrent respiratory infections in children. Minerva Pediatr 66:363-367, 2014.
12. Namazova-Baranova LS, Alekseeva AA, Kharit SM, Kozhevnikova TN, Taranushenko TE, Tuzankina IA and Scarci F: Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: A multicentre study. Int J Immunopathol Pharmacol 27:413-419, 1900.
13. Carta S, Silvestri M and Rossi GA: Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital J Pediatr 39:29, 2013.
14. Migliorati G, Nicoletti I and Riccardi C: Immunomodulating activity of pidotimod. Arzneimittelforschung 44:1421-1424, 1994.
15. Hu X, Zhang W, Wang L, Wan N, Wang B, Li W, Hua H, Hu X and Shan F: The detailed analysis of the changes of murine dendritic cells (DCs) induced by thymic peptide: Pidotimod (PTD). Hum Vaccin Immunother 8:1250-1258, 2012.
16. Hu S, Fu X, Fu A, Wei D, Ji J and Li W: The regulatory peptide pidotimod facilitates M2 macrophage polarization and its function. Amino Acids 46:1177-1185, 2014.
17. Shen HH, Ochkur SI, McGarry MP, Crosby JR, Hines EM, Borchers MT, Wang H, Biechelle TL, O'Neill KR, Ansay TL, et al: A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol 170:3296-3305, 2003.
18. Tong J, Bandulwala HS, Clay BS, Anders RA, Shilling RA, Balachandran DD, Chen B, Weinstock JV, Solway J, Hamann KJ and Sperling AI: Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. J Exp Med 203:1173-1184, 2006.
19. Bandukwala HS, Clay BS, Tong J, Mody PD, Cannon JL, Shilling RA, Verbeek JS, Weinstock JV, Solway J and Sperling AI: Signaling through Fc gamma RIII is required for optimal T helper type (Th) 2 responses and Th2-mediated airway inflammation. J Exp Med 204:1875-1889, 2007.
20. Barnes PJ: Th2 cytokines and asthma: An introduction. Respir Res 2:64-65, 2001.
21. Wang J, Fei LI, Yang M, Wu J, Zhao J, Gong W, Liu W, Bi W and Dong L: FIZZ1 promotes airway remodeling through the PI3K/Akt signaling pathway in asthma. Exp Ther Med 7:1265-1270, 2014.
22. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH and Meurs H: Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 20:179-186, 2010.
23. Hankin CS and Cox L: Allergy immunotherapy: What is the evidence for cost saving? Curr Opin Allergy Clin Immunol 14:363-370, 2014.
24. Li XM: Treatment of Asthma and Food Allergy With Herbal Interventions From Traditional Chinese Medicine. Mt Sinai J Med 78:697-716, 2011.
25. Nials AT and Uddin S: Mouse models of allergic asthma: Acute and chronic allergen challenge. Dis Models Mech 1:213-220, 2008.
26. Gries DM, Moffitt DR, Pulos E and Carter ER: A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 136:298-303, 2000.
27. Zhao J, Yeong LH and Wong WS: Dexamethasone alters bronchoalveolar lavage fluid proteome in a mouse asthma model. Int Arch Allergy Immunol 142:219-229, 2006.
28. Schleimer RP: An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 45(Suppl 1):S3-S7, 1993.
29. Gourgiotis D, Papadopoulos NG, Bossios A, Zamanis P and Saxoni-Papageorgiou P: Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma 41:285-287, 2004.
30. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombacher F and Bottomly K: Th2-induced airway mucus production is dependent on IL-4Ralpha, but not on eosinophils. J Immunol 162:6178-6183, 1999.
31. Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A and Gelfand EW: The role of IL-13 in established allergic airway disease. J Immunol 169:6482-6489, 2002.
32. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, et al: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19:4046-4055, 2000.
33. Dong L, Wang SJ, Camoretti-Mercado B, Li HJ, Chen M and Bi WX: FIZZ1 plays a crucial role in early stage airway remodeling of OVA-induced asthma. J Asthma 45:648-653, 2008.
34. Baldwin L and Roche WR: Does remodelling of the airway wall precede asthma? Paediatr Respir Rev 3:315-320, 2002.
35. Teng X, Li D, Champion HC and Johns RA: FIZZl/RELMalpha, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circ Res 92:1065-1067, 2003.
36. Zhang L, Wang M, Kang X, Boontheung P, Li N, Nel AE and Loo JA: Oxidative stress and asthma: Proteome analysis of chitinase-like proteins and FIZZ1 in lung tissue and bronchoalveolar lavage fluid. J Proteome Res 8:1631-1638, 2009.
37. Knippenberg S, Brumshagen C, Aschenbrenner F, Welte T and Maus UA: Arginase 1 activity worsens lung-protective immunity against Streptococcus pneumoniae infection. Eur J Immunol 45:1716-1726, 2015.
38. Maarsingh H, Zaagsma J and Meurs H: Arginase: A key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 158:652-664, 2009.
39. Maarsingh H, Pera T and Meurs H: Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol 378:171-184, 2008.
40. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA and Morris SM Jr: Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 170:148-153, 2004.
41. Maarsingh H, Dekkers BG, Zuidhof AB, Bos IS, Menzen MH, Klein T, Flik G, Zaagsma J and Meurs H: Increased arginase activity contributes to airway remodelling in chronic allergic asthma. Eur Respir J 38:318-328, 2011.
42. Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmmermann N, Mahalingam S, Webb DC, Tremethick DJ, Thompson PJ, Hogan SP, et al: Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol 177:5595-5603, 2006.
43. North ML, Khanna N, Marsden PA, Grasemann H and Scott JA: Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. Am J Physiol Lung Cell Mol Physiol 296:L911-L920, 2009.